- Details
- Fred Saad joins Alicia Morgans in a discussion on the final overall survival data from the PROpel trial, a randomized controlled trial aimed to address the first-line mCRPC question in patients who have not been treated with a novel hormonal agent in the mCRPC setting. Patients were randomized to receive abiraterone and prednisone or abiraterone and olaparib. The trial's primary endpoint was radio...
|
- Details
- Alicia Morgans is joined by Noel Clarke to discuss his work in clinically relevant biomarkers in castration-resistant prostate cancer (CRPC). Professor Clarke emphasizes the importance of using the available data that you have, keeping the patient at the very center of your thought processes, and regarding the patient as a whole rather than someone with prostate cancer. He highlights factors such...
|
- Details
- Oliver Sartor and Alicia Morgans discuss the TRITON 3 clinical trial. TRITON 3 is a phase three clinical trial observing how patients with metastatic castration-resistant prostate cancer with a homologous recombination gene deficiency respond to treatment with rucaparib versus treatment with a physician’s choice of abiraterone, enzalutamide, or docetaxel. Results found that rucaparib improved radi...
|
- Details
- In this conversation, Alicia Morgans and Alan Bryce highlighted the TRITON3 study. TRITON3 is a Phase 3, multicenter, open-label, randomized trial of Rubraca in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). The study enrolled 405 patients with a mutation in BRCA or ATM who were randomized to Rubraca or the control group, which consisted of the physician’...
|
- Details
- At the 2022 Large Urology Group Practice Association (LUGPA) annual meeting, Emmanuel Antonarakis presented on Genetic and Genomic Testing in Prostate Cancer. Biography: Emmanuel Antonarakis, MD, Genitourinary Oncologist, Clark Endowed Professor of Medicine, Division of Hematology, Oncology and Transplantation, Associate Director of Translational Research, Masonic Cancer Center, The University of...
|
- Details
- Fred Saad joins Alicia Morgans in a discussion focusing on the biomarker analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). This updated analysis provides more detail on patients with HRR mutations in the PROpel trial. In this biomarker a...
|
- Details
- Veda Giri joins Charles Ryan in a discussion on the EXPAND Network, EX tending P rostate Cancer Genetic A wareness, N avigation, and D elivery for genetic testing, and genetic awareness in males of African descent for Black men. This project is supported by the 2021 PCF-Pfizer Health Equity Challenge Award grant mechanism. Dr. Giri provides the rationale for this project stemming from statistics f...
|
- Details
- Maha Hussain is discussing the BRCAAway with Alicia Morgans, based upon Dr Hussain's presentation at ASCO 2022. The BRCAAway Trial is a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with mCRPC with DNA repair defects either in the tumor or germline. The PARP-inhibitor olaparib is approved for mCRPC patients with deleterious germline or somatic homologous...
|
- Details
- Elena Castro and Joaquin Mateo join Alicia Morgans in a conversation on data related to genetic testing, PARP inhibitors, and the data we saw come out of GU ASCO with the PROpel and MAGNITUDE trials and they discuss how this data impacts the use of PARP inhibitors in castrate-resistant prostate cancer (CRPC). Drs. Castro, Mateo, and Morgans discuss this data in terms of next-generation sequencing...
|
- Details
- Joining Alicia Morgans is Neal Shore to further highlight his team's presentation at this year's GU ASCO 2022 Annual Meeting focusing on evaluating the feasibility of instituting a hereditary cancer risk assessment (HCRA) protocol in their urological practice for prostate cancer patients. The results found were encouraging for the incorporation of recommended genomic screenings in community urolog...
|